Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

Avaxia Biologics
128 Spring Street, Suite 620
Lexington, MA 2421
Phone: 781-861-0062

Avaxia is a leader in the growing field of gut-targeted therapeutics - orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia's lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia is using its proprietary oral antibody platform to develop gut-targeted therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome and oral mucositis

Key Contact
Name
Barbara Fox
Title
CEO
E-Mail
Funding Events

Date
Amount
Type
Investors
Valuation
12/18/12 $6,400,000 Series B Beacon Angels
Beta Fund
Boston Harbor Angels
Cherrystone Angels
Golden Seeds
Granite State Angels
Keiretsu Forum
Maine Angels
North Country Angels
undisclosed
06/07/13 $11,400,000 Series B AbbVie Biotech Ventures
Ariel Savannah Angel Partners
Beacon Angels
Boston Harbor Angels
Cherrystone Angels
Golden Seeds
Launchpad Venture Group
Mass Medical Angels
Tech Coast Angels
undisclosed